Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics (OTCQB: SEOVF) generates frequent news as a clinical-stage regenerative medicine company advancing its Cell Pouch Bio-hybrid Organ platform for type 1 diabetes (T1D) and other chronic diseases. Its announcements focus on clinical progress, scientific collaborations, financing activities, and corporate developments that shape the trajectory of its T1D and thyroid disorder programs.
News releases from Sernova highlight interim data from its ongoing Phase 1/2 clinical trial in T1D, including reports of islet engraftment in the Cell Pouch, insulin production indicated by C-peptide, achievement of insulin independence in some patients, and improvements in HbA1c and patient-reported quality-of-life measures. These updates are central for readers tracking how the Cell Pouch Bio-hybrid Organ performs in people living with T1D, particularly those with hypoglycemia unawareness and severe hypoglycemic episodes.
Investors and observers can also follow collaborations and partnerships, such as Sernova’s agreements with Evotec for stem cell-derived islet-like clusters and with Eledon Pharmaceuticals to evaluate the immunosuppressive agent tegoprubart in a future cohort of its T1D trial. In addition, Sernova regularly reports on financing transactions, including loans, convertible debentures, and debt-to-equity conversions, which the company states are used to support working capital and clinical development plans.
Corporate governance and leadership changes, conference presentations, and updates from the company’s Data and Safety Management Board (DSMB) also appear in Sernova’s news flow. This page aggregates these items so readers can review clinical milestones, partnership developments, and capital structure updates related to Sernova Biotherapeutics and its SEOVF listing in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sernova Corp. (TSX:SVA; OTCQB:SEOVF) announced promising preclinical results for its partnership with Evotec SE, focusing on iPSC-derived islet-like clusters (ILCs) for treating Type 1 Diabetes (T1D). Key findings showcased that Evotec's scalable GMP manufacturing process yields ILCs with high insulin-producing beta cell content and successful glycemic control in diabetic mouse models. Results indicated that ILCs implanted in Sernova's Cell Pouch demonstrated blood sugar normalization akin to human islets over a 320-day study. The companies are on track for an IND filing and Phase 1/2 clinical trial in 2024, aiming to offer a commercially viable off-the-shelf treatment for diabetes. The preclinical data was presented at the IPITA/HSCI/JDRF Summit in April 2023, underscoring the significant potential for a 'functional cure' for T1D.
Sernova Corp. (OTCQB:SEOVF), a leader in cell therapeutics, announces that CEO Dr. Philip Toleikis will present at the Cell & Gene Meeting on the Med in Barcelona, Spain, from April 12-14, 2023. The presentation, titled Navigating CGTx Development in 2023, is scheduled for April 12, 2023, from 4:45 PM to 5:30 PM CET at the BioCentriq Ballroom. Virtual attendance will be available, providing access to Sernova’s presentation and all on-demand conference sessions. Credentialed investors can attend for free by contacting Laura Stringham. Sernova focuses on developing cell therapies for chronic diseases, including its Cell Pouch System aimed at providing a functional cure for insulin-dependent diabetes. This system fosters the long-term survival of therapeutic cells, promising advancements in treating chronic conditions.
Sernova Corp. addressed misleading claims from dissident shareholders regarding its board renewal process and proxy battle. The company asserts that its management has positioned Sernova for value creation, evidenced by a 17% year-to-date share price increase, outperforming the 8% decline in the Nasdaq XBI biotech index. Despite challenges in the biotech sector, Sernova's clinical trial advancements and technology partnerships, specifically with Evotec SE, are poised to enhance shareholder value. Upcoming milestones include clinical trial updates for type-1 diabetes and a hypothyroid disease program. Sernova ended Q1 2023 with cash resources of $45.6 million, providing a solid financial foundation for ongoing and future projects.
Sernova Corp. (OTCQB:SEOVF) announced that an abstract will be presented at the American Diabetes Association 83rd Scientific Sessions from June 23-26, 2023, in San Diego, CA. The abstract titled "Islet Allotransplantation into Pre-vascularized Sernova Cell Pouch" will be delivered on June 24 at 5:15 PM PT. This significant presentation showcases early results from the University of Chicago concerning Sernova's innovative Cell Pouch System, which aims to provide a functional cure for insulin-dependent diabetes. The study may impact future treatment approaches and is part of Sernova's broader strategy to develop cell therapies for chronic diseases.